Published in Nat Protoc on October 20, 2011
Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLoS Biol (2015) 2.30
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun (2012) 1.05
The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem (2012) 1.05
The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun (2015) 1.04
Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One (2013) 0.97
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer. Nat Chem Biol (2012) 0.92
Dependence of cancer cell adhesion kinetics on integrin ligand surface density measured by a high-throughput label-free resonant waveguide grating biosensor. Sci Rep (2014) 0.91
Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther (2012) 0.88
Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J (2012) 0.88
Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther (2014) 0.83
Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol (2015) 0.83
Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol (2013) 0.82
Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system. Br J Pharmacol (2013) 0.81
The Orphan G Protein-coupled Receptor GPR17 Negatively Regulates Oligodendrocyte Differentiation via Gαi/o and Its Downstream Effector Molecules. J Biol Chem (2015) 0.80
GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling. PLoS One (2016) 0.80
The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell Signal (2016) 0.79
New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling. Biochem Pharmacol (2014) 0.79
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One (2012) 0.78
Attenuation of inflammatory and neuropathic pain behaviors in mice through activation of free fatty acid receptor GPR40. Mol Pain (2015) 0.77
Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts. Pharmacol Res Perspect (2014) 0.77
Functional Divergence in the Role of N-Linked Glycosylation in Smoothened Signaling. PLoS Genet (2015) 0.77
Fluorescence-based high-throughput functional profiling of ligand-gated ion channels at the level of single cells. PLoS One (2013) 0.76
A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons. J Biol Chem (2016) 0.76
Intensity interrogation near cutoff resonance for label-free cellular profiling. Sci Rep (2016) 0.76
Planar Photonic Crystal Biosensor for Quantitative Label-Free Cell Attachment Microscopy. Adv Opt Mater (2015) 0.75
WNT Stimulation Dissociates a Frizzled 4 Inactive-State Complex with Gα12/13. Mol Pharmacol (2016) 0.75
The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells. FEBS Open Bio (2016) 0.75
A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor. Assay Drug Dev Technol (2014) 0.75
Deciphering and modulating G protein signalling in C. elegans using the DREADD technology. Sci Rep (2016) 0.75
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 5.76
Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A (2003) 3.75
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
A morphological biosensor for mammalian cells. Nature (1993) 2.57
The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci (2007) 2.46
A novel Galphaq/11-selective inhibitor. J Biol Chem (2004) 2.45
Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci U S A (2004) 2.43
Resonant waveguide grating biosensor for living cell sensing. Biophys J (2006) 2.17
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci (2007) 2.13
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov (2009) 1.45
Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal Chem (2005) 1.35
Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem (2008) 1.25
Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol (2010) 1.20
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J (2008) 1.17
Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A (2010) 1.13
Functional crosstalk between GPCRs: with or without oligomerization. Curr Opin Pharmacol (2009) 1.12
Label-free whole-cell assays: expanding the scope of GPCR screening. Drug Discov Today (2010) 1.12
Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem (2011) 1.09
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ (2007) 1.09
The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation. J Biol Chem (2008) 1.01
Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol (2009) 1.00
Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array. J Biomol Screen (2006) 0.98
Cellular dielectric spectroscopy: a powerful new approach to label-free cellular analysis. J Biomol Screen (2004) 0.95
Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40. J Biol Chem (2011) 0.93
5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils. J Allergy Clin Immunol (2005) 0.92
7TM pharmacology measured by label-free: a holistic approach to cell signalling. Curr Opin Pharmacol (2009) 0.90
A holistic view of GPCR signaling. Nat Biotechnol (2010) 0.85
Real-time and label-free detection of cellular response to signaling mediated by distinct subclasses of epidermal growth factor receptors. Anal Chem (2011) 0.83
Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors. Assay Drug Dev Technol (2011) 0.83
On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol (2006) 0.82
Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09
Improving health through policies that promote active travel: a review of evidence to support integrated health impact assessment. Environ Int (2011) 2.68
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A (2005) 2.31
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol (2006) 2.09
The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol (2007) 1.92
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89
Delay in treatment of colorectal cancer: multifactorial problem. World J Surg (2003) 1.89
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev (2008) 1.80
Heterotrimeric G-proteins: a short history. Br J Pharmacol (2006) 1.79
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J (2008) 1.73
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem (2006) 1.70
Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors. Mol Pharmacol (2005) 1.67
Parental smoking and children's respiratory health: independent effects of prenatal and postnatal exposure. Tob Control (2006) 1.66
Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.63
G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation (2005) 1.57
Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal (2010) 1.54
Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol (2005) 1.54
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci (2004) 1.53
Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci (2002) 1.53
Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine (2009) 1.50
Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo. Exp Biol Med (Maywood) (2010) 1.48
BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48
Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci (2002) 1.47
Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3. Mol Pharmacol (2007) 1.43
Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem (2006) 1.43
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci (2003) 1.41
GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39
Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer (2013) 1.38
Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol (2005) 1.33
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Neurobehavioral effects of exposure to traffic-related air pollution and transportation noise in primary schoolchildren. Environ Res (2012) 1.27
The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem (2005) 1.27
Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem (2008) 1.25
Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J Clin Invest (2007) 1.23
Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell Signal (2002) 1.22
Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochem J (2010) 1.22
Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem (2008) 1.21
Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol Sci (2005) 1.21
Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. J Cell Sci (2011) 1.21
The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem (2009) 1.21
GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res (2011) 1.21
The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol (2013) 1.18
Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells (2012) 1.18
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J (2008) 1.17
When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol (2010) 1.17
Discovery of a potent and selective GPR120 agonist. J Med Chem (2012) 1.16
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res (2007) 1.15
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.14
Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Mol Ther (2010) 1.13
Biosynthesis and accumulation of ergoline alkaloids in a mutualistic association between Ipomoea asarifolia (Convolvulaceae) and a clavicipitalean fungus. Plant Physiol (2008) 1.12
Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem (2005) 1.12
Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol (2006) 1.12
Multiple interactions between transmembrane helices generate the oligomeric alpha1b-adrenoceptor. Mol Pharmacol (2004) 1.10
Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays. Biochem J (2007) 1.10
Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem (2011) 1.09
Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol (2002) 1.09
Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem (2008) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric beta2-adrenoceptor. Cell Signal (2007) 1.08
The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochem J (2013) 1.08
Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney Int (2009) 1.08
Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol (2010) 1.07
Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J Biol Chem (2003) 1.07
A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg Med Chem Lett (2005) 1.06
The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem (2006) 1.06
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J Med Chem (2012) 1.06
A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Hum Mutat (2012) 1.06